周三，雅培实验室 (NYSE:ABT) 报告第四季度销售额为109.7亿美元，同比增长7.2%，低于市场预期的110.1亿美元。基础业务有机销售增长为8.8%，剔除COVID-19检测相关销售的有机增长为10.1%。调整后的每股摊薄收益为1.34美元，与分析师预期及管理层共识1.31-1.37美元一致，高于去年同期的1.19美元。雅培主席兼首席执行官罗伯特·福特表示，“我们在年内取得了强劲的势头。第四季度的销售增长和每股收益增长是全年最高的。”医疗器械销售增长13.7%，达到50.5亿美元，有机增长为14%。糖尿病护理方面，连续血糖监测仪的销售额为18亿美元，报告增长22.7%，有机增长22.8%。全球COVID-19检测销售在2024年第四季度为1.76亿美元，而去年同期为2.88亿美元。剔除COVID-19检测相关销售，全球诊断销售增长4.3%（有机增长6.1%）。雅培预计2025年全年调整后每股收益为5.05-5.25美元，市场共识为5.16美元，有机销售增长为7.5%-8.5%，调整后经营利润率为23.5%-24.0%。公司预计2025年第一季度调整后每股收益为1.05-1.09美元，市场共识为1.11美元。
以上内容来自Benzinga Earnings专栏，原文如下：
On Wednesday, Abbott Laboratories (NYSE:ABT) reported fourth-quarter sales of $10.97 billion, up 7.2% year over year, missing the consensus of $11.01 billion.
Organic sales growth for the underlying base business was 8.8%. Organic growth, excluding COVID-19 testing-related sales was 10.1%.
Adjusted diluted earnings per share were $1.34, in line with the analyst estimates and management consensus of $1.31-$1.37, up from $1.19 a year ago.
Also Read: FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch
“We finished the year with very strong momentum. Sales growth and earnings per share growth in the fourth quarter were the highest of the year,” said Robert Ford, chairman and chief executive officer.
“We continued our track record for delivering on our commitments by achieving the upper end of our initial guidance ranges for 2024 and are well-positioned to deliver another year of strong growth in 2025.”
Medical Device sales increased 13.7% to $5.05 billion and 14% organically, including double-digit growth in the U.S. and internationally.
Several products contributed, including FreeStyle Libre, Navitor, TriClip, Amplatzer Amulet, and AVEIR.
In Diabetes Care, sales of continuous glucose monitors were $1.8 billion and grew 22.7% on a reported basis and 22.8% organically.
Nutrition sales increased by 4.5% to $2.07 billion (+7.1% organically). In Pediatric Nutrition, global sales increased by 1.5% (+2.5%), reflecting continued market share gains in the infant formula business. Adult nutrition sales increased 7.4% (+11.4%), led by the Ensur and Glucerna brands.
Worldwide COVID-19 testing sales were $176 million in the fourth quarter of 2024 compared to $288 million a year ago. Excluding COVID-19 testing-related sales, global Diagnostics sales increased 4.3% (+6.1%). Excluding COVID-19 testing-related sales, growth in Rapid Diagnostics was driven by strong demand for Abbott’s portfolio of respiratory disease tests.
Guidance: Abbott projects full-year 2025 adjusted EPS of $5.05-$5.25 versus a consensus of $5.16, with organic sales growth of 7.5%- 8.5% and an adjusted operating margin of 23.5%- 24.0%.
Abbott Laboratories expects first quarter 2025 adjusted EPS of $1.05-$1.09 versus consensus of $1.11.
Price Action: ABT stock is up 0.72% at $117.64 at the last check Wednesday.
Read Next:
Photo by Sundry Photography via Shutterstock
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.